Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 9/20 | 0.81 |
| ▸ | MBOAT4 | Q96T53 | 4/20 | 0.69 |
| ▸ | CCR6 | P51684 | 1/20 | 0.69 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.60 |
| ▸ | USP7 | Q93009 | 2/20 | 0.60 |
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | STAT3 | P40763 | 1/20 | 0.60 |
| ▸ | RORC | P51449 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24337080 | 0.92 | NOS2 (0.79) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL24337158 | 0.90 | NOS2 (0.83) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL17553175 | 0.89 | NOS2 (1.00) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL19380278 | 0.89 | NOS2 (1.00) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL22345141 | 0.89 | NOS2 (1.00) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL23897711 | 0.89 | NOS2 (1.00) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL24337036 | 0.89 | NOS2 (1.00) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL24337272 | 0.89 | NOS2 (0.82) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL24337081 | 0.89 | NOS2 (0.80) | NOS2MBOAT4CCR6KEAP1CYP3A4 | |
| SCHEMBL24336900 | 0.89 | NOS2 (0.80) | NOS2MBOAT4CCR6KEAP1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365621-A1 | ANALOGS OF CDDO-2P-IM AND CDDO-3P-IM | TRITERPENOID THERAPEUTICS INC (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365621-A1 | ANALOGS OF CDDO-2P-IM AND CDDO-3P-IM | TRITERPENOID THERAPEUTICS INC (US) | 2023-11-16 | — | — | US | disclosed |
| WO-2022056439-A1 | ANALOGS OF CDDO-2P-IM AND CDDO-3P-IM | TRITERPENOID THERAPEUTICS, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365621-A1 | ANALOGS OF CDDO-2P-IM AND CDDO-3P-IM | CDYL2, CYP11B2, HSD17B13 | NOS2 1980/4885MBOAT4 3144/4885CCR6 4292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.